Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VCA followed by D-MAG in elderly AML
NCT05603884Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and mitoxantrone-liposome in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Remission Rate at 6 months. Started Dec 2022; status: recruiting.
02
Drugs
tucidinostatmitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05603884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05603884.